title: Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hirata
authors.forename: Taiji
authors.initials: T
authors.lastname: Yokote
authors.forename: Kichinosuke
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Shoko
authors.initials: S
authors.lastname: Nakayama
authors.forename: Takuji
authors.initials: T
authors.lastname: Miyoshi
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Akioka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hara
authors.forename: Motomu
authors.initials: M
authors.lastname: Tsuji
authors.forename: Takayuki
authors.initials: T
authors.lastname: Takubo
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hanafusa
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab